Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.
Saved in:
| Title: | Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial. |
|---|---|
| Authors: | Wei ZG; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China., Chen HJ; Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang DJ; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Jiang Z; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Pei YY; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Li LY; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang F; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Jin J; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Liu ZR; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Chen F; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. hxchenfei@163.com., Liu J; Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn.; Head and Neck Surgical Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. junliu@wchscu.edu.cn., Peng XC; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com.; Sichuan Provincial Key Laboratory of Nuclear Physics and Medical Research, Sichuan University, Chengdu, People's Republic of China. pxx2014@163.com. |
| Source: | Nature communications [Nat Commun] 2025 Oct 07; Vol. 16 (1), pp. 8918. Date of Electronic Publication: 2025 Oct 07. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-63978-y |
